The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.
Female using Rogaine foam for hair loss had scalp punch biopsy, diagnosed with Androgenetic Alopecia (AGA). Doctor recommended starting Spironolactone 50mg.
The conversation is about a group of people trying KX-826 for hair loss, with no serious side effects reported after 25 days of use. Some participants are experiencing less scalp itch and shedding, but it's too early for definitive results.
Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
Creatine may cause increased hair shedding in some individuals, especially those with androgenetic alopecia (AGA), despite its physical performance benefits. Many users report stopping creatine to reduce hair loss, while others believe the effects are anecdotal or due to other factors like increased physical activity.
A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.
The conversation discusses hair thinning and the potential role of vitamin D deficiency in hair loss, with suggestions to take vitamin D3 supplements. The user also mentions having diffuse thinning and a slightly receding hairline.
The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
The user is experiencing rapid hair loss, progressing from Norwood 3 to 7, with thinning at the crown and receding hairline. Suggested treatments include finasteride, minoxidil, ketoconazole shampoo, and CBD with MCT oil.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.
The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.